VolitionRx Announces Termination of CEO Position at Subsidiary

TradingView
2025.12.11 22:03
portai
I'm PortAI, I can summarize articles.

On December 5, 2025, VolitionRx Ltd announced the termination of Dr. Salvatore Thomas Butera as CEO of its subsidiary, Volition Veterinary Diagnostics Development, effective January 31, 2026, as part of cost-realignment efforts.IndividualDr. Salvatore Thomas ButeraRoleCEO of Volition VeterinaryType of ChangeTerminatedEffective DateJanuary 31, 2026ReasonOperational reasonsReplacement InfoPosition eliminatedBackground DetailsN/ABoard/Committee Role ChangesNot disclosedOriginal SEC Filing: VOLITIONRX LTD [ VNRX ] - 8-K - Dec. 11, 2025DisclaimerThis is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer